Purchase this article with an account.
Akio Oishi, Michiko Mandai, Mikiko Kimakura, Akihiro Nishida, Yasuo Kurimoto; Predictive Factors Of Chorioretinal Atrophy Progression After Anti-VEGF Therapy For Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2721.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To explore the predictive factors of development or enlargement of chorioretinal atrophy after anti-VEGF therapy for myopic choroidal neovascularization (mCNV).
We investigated 35 patients with mCNV who underwent intravitreal injection of ranibizumab or bevacizumab and followed up for more than 12 months. Fundus photographs before the treatment and at the final visit were compared and judged if the chorioretinal atrophy developed or enlarged. A multivariate analysis was performed using stepwise logistic regression analysis to determine the independent predictors of progression of chorioretinal atrophy. The analyzed factors consisted of age, axial length, CNV area, previous photodynamic therapy, preoperative visual acuity (logMAR), number of injections, and the observation period.
Chorioretinal atrophy developed or enlarged in 9 cases. Among the above factors, only preoperative logMAR was a significant factor of development or enlargement of chorioretinal atrophy (odds ratio, 16.0, 95%CI 1.5-174.1: one unit change of logMAR increases or decreases the risk of chorioretinal atrophy by 16 folds).
Preoperative poor visual acuity is a risk factor of progression of chorioretinal atrophy in mCNV patients treated with anti-VEGF therapy.
This PDF is available to Subscribers Only